{"id":"d-0120","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PI3K delta subunit, D-0120 reduces the activity of the PI3K/AKT signaling pathway, which is involved in the proliferation and survival of immune cells. This leads to a decrease in the production of inflammatory cytokines and an increase in the production of anti-inflammatory cytokines.","oneSentence":"D-0120 is a small molecule inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:30:39.608Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia (CLL)"}]},"trialDetails":[{"nctId":"NCT05665699","phase":"PHASE2","title":"Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout","status":"ACTIVE_NOT_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2023-04-17","conditions":"Gout","enrollment":80},{"nctId":"NCT05504083","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2022-09-28","conditions":"Hyperuricemia","enrollment":121},{"nctId":"NCT05360628","phase":"EARLY_PHASE1","title":"Evaluation of PK and Safety of D-0120 and Allopurinol","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2021-11-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT03923868","phase":"PHASE1, PHASE2","title":"D-0120 Safety and PK/PD Study in China","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2019-04-18","conditions":"Hyperuricemia or Gout","enrollment":52},{"nctId":"NCT04097405","phase":"PHASE1","title":"Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2019-09-18","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT03291782","phase":"PHASE1","title":"D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2017-09-13","conditions":"Gout","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"D-0120","genericName":"D-0120","companyName":"InventisBio Co., Ltd","companyId":"inventisbio-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"D-0120 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}